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Abstract
Chemotherapy-induced neuropathic pain is one of the major problems for cancer patients. Although paclitaxel
and cisplatin are widely used in women, most laboratory studies of chemotherapy-induced neuropathic pain
have been conducted on male animals. The current study examined the gender differences in chemotherapy-
induced neuropathic pain in mice. Neuropathic pain was induced by intraperitoneal injection of paclitaxel
(2mg/kg) for five consecutive days and cisplatin (1mg/kg) for seven consecutive days. Cold allodynia was
evaluated by measuring the paw withdrawal frequency and duration of paw licking in mice; however, mech-
anical allodynia was assessed by von Frey filaments. Neuropathic pain began to manifest after a few days
(P< 0.001). Cold allodynia was more robust in female mice (P< 0.001) treated with paclitaxel, while no dif-
ferences were observed between the two genders in the manifestation of paclitaxel-induced mechanical
allodynia. Interestingly, no gender differences were observed in cisplatin-induced cold and mechanical allo-
dynia tests. In conclusion, gender differences play a major role in neuropathic pain induced by paclitaxel. The
differences between male and female animals should be considered in future studies and the findings should
be generalized to humans with caution.
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It is believed that gender diﬀerences exist in the path-
ology of chronic and neuropathic pain.1 Various clin-
ical studies have proposed that women are more
sensitive to pain than men.2,3 Furthermore, animal
studies have demonstrated that female rodents show
a lower threshold for pain in diﬀerent models; how-
ever, the underlying mechanisms are not well under-
stood.4 Chemotherapy-induced neuropathic pain is
one of the major side-eﬀects in cancer treatment
using taxane and platinum complexes.5 The pain is
characterized by numbness, tingling, burning sensa-
tion and cold allodynia.6 Neuropathic pain may
impair the patient’s quality of life and compromise a
patient’s ability to tolerate chemotherapy.7 The risk
of neuropathy is proportional to the dose and dur-
ation of administration of chemotherapeutic
agents.8,9 There is no established approach to the pre-
vention and treatment of chemotherapy-induced
nerve damage.10
Paclitaxel and cisplatin cause signiﬁcant neuro-
pathic pain. These are major drugs for the treatment
of breast and ovarian cancers and are widely used
in female patients.8 Diﬀerent animal models are avail-
able to investigate the eﬀectiveness of these treat-
ments.11,12 Rats and mice are frequently used to
evaluate mechanical and cold allodynia tests.13
These tests are predominantly performed on male
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animals. Sometimes researchers ignore the role of
gender in experiments whereas others believe that
the female hormonal cycle can cause problematic
variations in their ﬁndings.14
However, the relation between levels of chemother-
apy-induced neuropathic pain and gender diﬀerences
has not yet been studied in mice. In this study, we inves-




NMRI mice (Pasteur institute, Tehran, Iran) weighing
20–30 g were used. The animals were housed under a
12 h light/dark cycle with free access to food and
water, and were assigned to diﬀerent treatment
groups (n¼ 6–8 in each group). All experiments were
conducted in accordance with the guidelines for the
care of laboratory animals of the Ethics Committee
of Isfahan University of Medical Sciences.
Drugs and drug administration
Cisplatin and paclitaxel were purchased from Sigma–
Aldrich Inc (St Louis, MO, USA). Cisplatin was freshly
dissolved in sterile saline, and paclitaxel was dissolved
in ethanol–cremophor–saline (5:5:90, v/v/v). Male and
female mice received paclitaxel (2mg/kg) intraperitone-
ally for ﬁve consecutive days with a cumulative dose of
10mg/kg, or vehicle.15 Cisplatin (1mg/kg) was intra-
peritoneally administered to male and female mice for
seven consecutive days. A control group received
saline.16
Behavioral assay
The mice were placed on top of an aluminum mesh
table and allowed to adjust to the situation for
approximately 15min. Brieﬂy, for the assessment of
cold allodynia, acetone was applied three times via a
needle and syringe to the plantar surface of each hind
paw with 30 s intervals.17 The time spent licking the
paw was recorded with a stopwatch. The frequency of
licking was calculated and expressed as a percentage
using the following formula (number of trial attending
the hind paw/total number of trial)100. For assess-
ment of mechanical allodynia, von Frey ﬁlaments
(Stoelting, Wood Dale, IL, USA) ranging from 0.16
to 6 g were used as previously described.18 Bending
force was applied to the plantar skin of the right
hind paw, and each application was held for 6 s,
using the up–down method to determine threshold
sensitivity.
Data analysis
Data are presented as mean standard deviation, and
were compared by one-way analysis of variance
(ANOVA) followed by Fisher LSD post hoc test for
multiple comparisons. Time-course analysis of behav-
ioral data was compared by repeated measures
ANOVA for each experimental group.
Results
Effects of paclitaxel on cold allodynia
Paw withdrawal frequency and duration of paw licking
increased in both genders after treatment with pacli-
taxel (2mg/kg, for 5 consecutive days). The control
group did not show any changes in nociceptive
response. Also paw withdrawal frequency and duration
of paw licking were more robust in female mice com-
pared with male mice or the control group (P< 0.001).
Interestingly, pain was manifested sooner in the female
mice than in the male mice (Figures 1a and 1b).
Effects of paclitaxel on mechanical allodynia
We evaluated withdrawal response to mechanical
stimulation using von Frey ﬁlaments. Paclitaxel (2mg/
kg, for 5 consecutive days) led to a signiﬁcant reduction
in paw withdrawal threshold in male and female mice
(P< 0.01) (Figure 2). However, we observed no signiﬁ-
cant diﬀerences in responses between male and female
mice during this period of time.
Effects of cisplatin on cold allodynia
Administration of cisplatin (1mg/kg) for seven days
evoked cold allodynia in treatment groups
(P< 0.001). Both paw withdrawal frequency and dur-
ation of paw licking increased in male and female mice.
However, no signiﬁcant diﬀerences were observed
between the genders (Figures 3a and b).
Effects of cisplatin on mechanical allodynia
As shown in Figure 4, a statistically signiﬁcant diﬀer-
ence was observed in the manifestation of mechanical
sensitivity between cisplatin-treated mice and the con-
trol group (P< 0.01), while no diﬀerences were
observed between the genders (Figure 4).
Discussion
The aim of this study was to evaluate the eﬀect of
gender diﬀerences on levels of chemotherapy-induced
neuropathic pain in mice. Paclitaxel and cisplatin are
frequently used for the treatment of breast and ovarian
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cancers; however, the vast majority of preclinical stu-
dies to identify the proper treatment for neuropathic
pain have been conducted using male mice. In this
study we sought to determine whether male mice are
good candidates for these models of pain. We showed
that paclitaxel-induced cold allodynia was more robust
in female mice. Interestingly, no gender diﬀerences were
observed for paclitaxel-induced mechanical allodynia-
and cisplatin-induced neuropathic pain.
Paclitaxel is used as a chemotherapeutic agent with
diﬀerent types of cancers such as breast, cervical and
ovarian cancers. It enhances microtubule polymeriza-
tion,19 but the mechanisms by which paclitaxel induces
neuropathic pain have not yet been demonstrated.7
Paclitaxel induces degeneration of axonal microtubules
but has no eﬀects on the axonal cytoskeleton.20 We
observed no diﬀerences in paclitaxel-induced mechan-
ical allodynia between male and female mice; and this
ﬁnding is consistent with a study which also showed no
gender diﬀerences in paclitaxel-induced mechanical
allodynia in rats.21 However, gender diﬀerences in
cold allodynia were not consistent with previous stu-
dies, possibly suggesting diﬀerent mechanisms are
involved. The diﬀerences between mice and rats have
already been noted during other behavioral studies. For
example, periorbital and forepaw thresholds, but not
hind paw thresholds, are reduced in mice with craniot-
omy in the migraine model. In contrast to mice, these
eﬀects are not observed in rats.22 It is believed that
mouse species are more susceptible than rats to pain
and stress.23 Behavioral diﬀerences also exist in
response to stressors, and signiﬁcant diﬀerences have
Figure 1. (a) Time course of paw withdrawal frequency after paclitaxel treatment. Paclitaxel (2mg/kg) was injected for
five consecutive days, and the control group received vehicle. A significant gender difference was observed for paclitaxel-
induced cold allodynia (**P< 0.01, ***P< 0.001 when compared with the control group, and ##P< 0.01, ###P< 0.001 when
compared with the male group). (b) Duration of paw licking after paclitaxel treatment. Paclitaxel (2mg/kg) was injected for
five consecutive days, and the control group received vehicle. A significant gender difference was observed for paclitaxel-
induced cold allodynia (**P< 0.01, ***P< 0.001 when compared with the control group, and ##P< 0.01, ###P< 0.001 when
compared with the male group. *P< 0.05, **P< 0.01, ***P< 0.001 when compared with the vehicle group, and ##P< 0.01,
###P< 0.001 when compared with the male group).
Figure 2. Paw withdrawal threshold after paclitaxel
treatment. Paclitaxel (2mg/kg) was injected for five con-
secutive days, and the control group received vehicle. No
significant gender difference was observed for paclitaxel-
induced mechanical allodynia (**P< 0.01 when compared
with the control group).
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been noted among species and even strains within
species.24
Cisplatin is widely used for the treatment of urinary,
bladder, and ovarian cancers.25 It has been reported
that sensory perception and sensory nerve conduction
are reduced following treatment with cisplatin.26 Nerve
biopsy evaluations have revealed loss of myelinated
ﬁbers.27 Analysis of dorsal root ganglion in animals
has shown atrophy of neuronal soma and nucleus.28
Sexual dimorphism exists in peripheral nerve abnorm-
alities. A study has demonstrated that mortality and
weight loss are more robust in male mice treated with
cispaltin.29 In the present study, we observed no diﬀer-
ences between male and female mice in cisplatin-
induced neuropathic pain. However, one other study
has found faster regeneration and functional recovery
in female animals.30
Vincristine induces neuropathic pain which is more
severe in females than in males,31 suggesting that the
impact of gender diﬀerence depends on the type of tests
and models. A large body of evidence has suggested
that endogenous sex steroid plays a major role in med-
iating sex diﬀerences in nociception. Pain modulation is
more eﬀective during the ovulatory phase than during
the early follicular and mid-luteal phases.32 There are
many possible mechanisms by which sex hormones may
aﬀect pain. For example, serotonergic and noradrener-
gic neurons in the nucleus raphe magnus and locus
coeruleus express estrogen and progesterone receptors
and interact with sex hormones, which leads to the
release of opioids in the spinal cord.33 Interaction
with N-methyl-D-aspartate (NMDA) receptors in the
spinal cord/brainstem is another mechanism; NMDA
receptor antagonists reduce the activity of neurons in
trigeminal subnucleus caudalis in an estrogen-depen-
dent manner.34
Experimental hyperalgesia models have shown sig-
niﬁcant gender diﬀerences; however, not all pain animal
Figure 3. (a) Paw withdrawal threshold frequency after cisplatin treatment. Cisplatin (1mg/kg) was injected for seven
consecutive days, and the control group received vehicle. No significant gender difference was observed for cisplatin-
induced cold allodynia (**P< 0.01, ***P< 0.001 when compared with the control group). (b) Duration of paw licking after
cisplatin treatment. Cisplatin (1mg/kg) was injected for seven consecutive days, and the control group received vehicle.
No significant gender difference was observed for cisplatin-induced cold allodynia (***P< 0.001 when compared with the
control group).
Figure 4. Paw withdrawal threshold frequency after cis-
platin treatment. Cisplatin (1mg/kg) was injected for seven
consecutive days, and the control group received vehicle.
No significant gender difference was observed for cispla-
tin-induced mechanical allodynia (**P< 0.01 when com-
pared with the control group).
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models show robust gender diﬀerences.35,36 Clinically,
pain is more pronounced in women, but few pain con-
ditions are predominant in men, including post trau-
matic headaches and abdominal migraines.37 These
studies suggest that diﬀerent mechanisms and risk fac-
tors may be involved in each gender.38
In conclusion, our study demonstrated that there
was no signiﬁcant gender diﬀerence in a mouse model
of cisplatin-induced neuropathic pain; however, a
gender diﬀerence was observed in paclitaxel-induced
cold, but not mechanical, allodynia.
It may therefore not be advisable to evaluate diﬀer-
ent analgesics in male animals, as there are many dif-
ferences between genders and among diﬀerent models.
Human studies should also be performed and the
results should be compared with animal studies to
determine the best model of pain for evaluating diﬀer-
ent drugs.
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